nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—ADRA2A—epilepsy syndrome	0.416	1	CbGaD
Guanabenz—CYP1A2—Carbamazepine—epilepsy syndrome	0.0359	0.203	CbGbCtD
Guanabenz—CYP1A2—Primidone—epilepsy syndrome	0.0335	0.19	CbGbCtD
Guanabenz—CYP1A2—Propofol—epilepsy syndrome	0.03	0.17	CbGbCtD
Guanabenz—CYP1A2—Phenobarbital—epilepsy syndrome	0.0287	0.162	CbGbCtD
Guanabenz—CYP1A2—Diazepam—epilepsy syndrome	0.0272	0.154	CbGbCtD
Guanabenz—CYP1A2—Valproic Acid—epilepsy syndrome	0.0214	0.121	CbGbCtD
Guanabenz—Guanfacine—ADRA2A—epilepsy syndrome	0.00206	0.58	CrCbGaD
Guanabenz—Guanfacine—CYP2C19—epilepsy syndrome	0.00149	0.42	CrCbGaD
Guanabenz—Skin disorder—Valproic Acid—epilepsy syndrome	7.96e-05	0.000277	CcSEcCtD
Guanabenz—Oedema peripheral—Topiramate—epilepsy syndrome	7.93e-05	0.000276	CcSEcCtD
Guanabenz—Cough—Pregabalin—epilepsy syndrome	7.92e-05	0.000276	CcSEcCtD
Guanabenz—Pruritus—Phenytoin—epilepsy syndrome	7.91e-05	0.000276	CcSEcCtD
Guanabenz—Connective tissue disorder—Topiramate—epilepsy syndrome	7.91e-05	0.000275	CcSEcCtD
Guanabenz—Nausea—Levetiracetam—epilepsy syndrome	7.91e-05	0.000275	CcSEcCtD
Guanabenz—Rash—Vigabatrin—epilepsy syndrome	7.9e-05	0.000275	CcSEcCtD
Guanabenz—Dizziness—Felbamate—epilepsy syndrome	7.89e-05	0.000275	CcSEcCtD
Guanabenz—Dermatitis—Vigabatrin—epilepsy syndrome	7.89e-05	0.000275	CcSEcCtD
Guanabenz—Pruritus—Oxcarbazepine—epilepsy syndrome	7.87e-05	0.000274	CcSEcCtD
Guanabenz—Hypersensitivity—Carbamazepine—epilepsy syndrome	7.86e-05	0.000274	CcSEcCtD
Guanabenz—Vision blurred—Gabapentin—epilepsy syndrome	7.85e-05	0.000273	CcSEcCtD
Guanabenz—Headache—Vigabatrin—epilepsy syndrome	7.85e-05	0.000273	CcSEcCtD
Guanabenz—Hypertension—Pregabalin—epilepsy syndrome	7.84e-05	0.000273	CcSEcCtD
Guanabenz—Vomiting—Diazepam—epilepsy syndrome	7.84e-05	0.000273	CcSEcCtD
Guanabenz—Anorexia—Valproic Acid—epilepsy syndrome	7.81e-05	0.000272	CcSEcCtD
Guanabenz—Rash—Diazepam—epilepsy syndrome	7.77e-05	0.000271	CcSEcCtD
Guanabenz—Dermatitis—Diazepam—epilepsy syndrome	7.77e-05	0.000271	CcSEcCtD
Guanabenz—Chest pain—Pregabalin—epilepsy syndrome	7.73e-05	0.000269	CcSEcCtD
Guanabenz—Myalgia—Pregabalin—epilepsy syndrome	7.73e-05	0.000269	CcSEcCtD
Guanabenz—Arthralgia—Pregabalin—epilepsy syndrome	7.73e-05	0.000269	CcSEcCtD
Guanabenz—Ill-defined disorder—Gabapentin—epilepsy syndrome	7.73e-05	0.000269	CcSEcCtD
Guanabenz—Dizziness—Zonisamide—epilepsy syndrome	7.72e-05	0.000269	CcSEcCtD
Guanabenz—Headache—Diazepam—epilepsy syndrome	7.72e-05	0.000269	CcSEcCtD
Guanabenz—Anxiety—Pregabalin—epilepsy syndrome	7.7e-05	0.000268	CcSEcCtD
Guanabenz—Diarrhoea—Clonazepam—epilepsy syndrome	7.7e-05	0.000268	CcSEcCtD
Guanabenz—Anaemia—Gabapentin—epilepsy syndrome	7.7e-05	0.000268	CcSEcCtD
Guanabenz—Hypotension—Valproic Acid—epilepsy syndrome	7.66e-05	0.000267	CcSEcCtD
Guanabenz—Asthenia—Carbamazepine—epilepsy syndrome	7.66e-05	0.000267	CcSEcCtD
Guanabenz—Agitation—Gabapentin—epilepsy syndrome	7.65e-05	0.000267	CcSEcCtD
Guanabenz—Diarrhoea—Phenytoin—epilepsy syndrome	7.65e-05	0.000267	CcSEcCtD
Guanabenz—Discomfort—Pregabalin—epilepsy syndrome	7.64e-05	0.000266	CcSEcCtD
Guanabenz—Nausea—Fosphenytoin—epilepsy syndrome	7.63e-05	0.000266	CcSEcCtD
Guanabenz—Diarrhoea—Oxcarbazepine—epilepsy syndrome	7.61e-05	0.000265	CcSEcCtD
Guanabenz—Erythema multiforme—Topiramate—epilepsy syndrome	7.61e-05	0.000265	CcSEcCtD
Guanabenz—Angioedema—Gabapentin—epilepsy syndrome	7.61e-05	0.000265	CcSEcCtD
Guanabenz—Hypersensitivity—Lamotrigine—epilepsy syndrome	7.6e-05	0.000265	CcSEcCtD
Guanabenz—Vomiting—Felbamate—epilepsy syndrome	7.59e-05	0.000264	CcSEcCtD
Guanabenz—Dry mouth—Pregabalin—epilepsy syndrome	7.56e-05	0.000263	CcSEcCtD
Guanabenz—Pruritus—Carbamazepine—epilepsy syndrome	7.55e-05	0.000263	CcSEcCtD
Guanabenz—Rash—Felbamate—epilepsy syndrome	7.52e-05	0.000262	CcSEcCtD
Guanabenz—Eye disorder—Topiramate—epilepsy syndrome	7.52e-05	0.000262	CcSEcCtD
Guanabenz—Dermatitis—Felbamate—epilepsy syndrome	7.52e-05	0.000262	CcSEcCtD
Guanabenz—Malaise—Gabapentin—epilepsy syndrome	7.51e-05	0.000262	CcSEcCtD
Guanabenz—Tinnitus—Topiramate—epilepsy syndrome	7.5e-05	0.000261	CcSEcCtD
Guanabenz—Headache—Felbamate—epilepsy syndrome	7.48e-05	0.00026	CcSEcCtD
Guanabenz—Confusional state—Pregabalin—epilepsy syndrome	7.47e-05	0.00026	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	7.47e-05	0.00026	CcSEcCtD
Guanabenz—Syncope—Gabapentin—epilepsy syndrome	7.47e-05	0.00026	CcSEcCtD
Guanabenz—Leukopenia—Gabapentin—epilepsy syndrome	7.45e-05	0.00026	CcSEcCtD
Guanabenz—Dizziness—Clonazepam—epilepsy syndrome	7.44e-05	0.000259	CcSEcCtD
Guanabenz—Nausea—Vigabatrin—epilepsy syndrome	7.44e-05	0.000259	CcSEcCtD
Guanabenz—Vomiting—Zonisamide—epilepsy syndrome	7.43e-05	0.000259	CcSEcCtD
Guanabenz—Oedema—Pregabalin—epilepsy syndrome	7.41e-05	0.000258	CcSEcCtD
Guanabenz—Asthenia—Lamotrigine—epilepsy syndrome	7.4e-05	0.000258	CcSEcCtD
Guanabenz—Dizziness—Phenytoin—epilepsy syndrome	7.39e-05	0.000258	CcSEcCtD
Guanabenz—Rash—Zonisamide—epilepsy syndrome	7.37e-05	0.000257	CcSEcCtD
Guanabenz—Infection—Pregabalin—epilepsy syndrome	7.36e-05	0.000256	CcSEcCtD
Guanabenz—Paraesthesia—Valproic Acid—epilepsy syndrome	7.36e-05	0.000256	CcSEcCtD
Guanabenz—Dermatitis—Zonisamide—epilepsy syndrome	7.36e-05	0.000256	CcSEcCtD
Guanabenz—Dizziness—Oxcarbazepine—epilepsy syndrome	7.36e-05	0.000256	CcSEcCtD
Guanabenz—Nausea—Diazepam—epilepsy syndrome	7.32e-05	0.000255	CcSEcCtD
Guanabenz—Loss of consciousness—Gabapentin—epilepsy syndrome	7.32e-05	0.000255	CcSEcCtD
Guanabenz—Headache—Zonisamide—epilepsy syndrome	7.32e-05	0.000255	CcSEcCtD
Guanabenz—Dyspnoea—Valproic Acid—epilepsy syndrome	7.31e-05	0.000255	CcSEcCtD
Guanabenz—Diarrhoea—Carbamazepine—epilepsy syndrome	7.3e-05	0.000254	CcSEcCtD
Guanabenz—Pruritus—Lamotrigine—epilepsy syndrome	7.3e-05	0.000254	CcSEcCtD
Guanabenz—Shock—Pregabalin—epilepsy syndrome	7.29e-05	0.000254	CcSEcCtD
Guanabenz—Immune system disorder—Topiramate—epilepsy syndrome	7.27e-05	0.000253	CcSEcCtD
Guanabenz—Nervous system disorder—Pregabalin—epilepsy syndrome	7.27e-05	0.000253	CcSEcCtD
Guanabenz—Cough—Gabapentin—epilepsy syndrome	7.27e-05	0.000253	CcSEcCtD
Guanabenz—Thrombocytopenia—Pregabalin—epilepsy syndrome	7.26e-05	0.000253	CcSEcCtD
Guanabenz—Mediastinal disorder—Topiramate—epilepsy syndrome	7.25e-05	0.000253	CcSEcCtD
Guanabenz—Tachycardia—Pregabalin—epilepsy syndrome	7.23e-05	0.000252	CcSEcCtD
Guanabenz—Chills—Topiramate—epilepsy syndrome	7.22e-05	0.000252	CcSEcCtD
Guanabenz—Dyspepsia—Valproic Acid—epilepsy syndrome	7.22e-05	0.000251	CcSEcCtD
Guanabenz—Skin disorder—Pregabalin—epilepsy syndrome	7.2e-05	0.000251	CcSEcCtD
Guanabenz—Hypertension—Gabapentin—epilepsy syndrome	7.19e-05	0.00025	CcSEcCtD
Guanabenz—Vomiting—Clonazepam—epilepsy syndrome	7.16e-05	0.000249	CcSEcCtD
Guanabenz—Decreased appetite—Valproic Acid—epilepsy syndrome	7.13e-05	0.000248	CcSEcCtD
Guanabenz—Vomiting—Phenytoin—epilepsy syndrome	7.11e-05	0.000248	CcSEcCtD
Guanabenz—Rash—Clonazepam—epilepsy syndrome	7.1e-05	0.000247	CcSEcCtD
Guanabenz—Dermatitis—Clonazepam—epilepsy syndrome	7.09e-05	0.000247	CcSEcCtD
Guanabenz—Myalgia—Gabapentin—epilepsy syndrome	7.09e-05	0.000247	CcSEcCtD
Guanabenz—Arthralgia—Gabapentin—epilepsy syndrome	7.09e-05	0.000247	CcSEcCtD
Guanabenz—Chest pain—Gabapentin—epilepsy syndrome	7.09e-05	0.000247	CcSEcCtD
Guanabenz—Nausea—Felbamate—epilepsy syndrome	7.09e-05	0.000247	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	7.08e-05	0.000247	CcSEcCtD
Guanabenz—Vomiting—Oxcarbazepine—epilepsy syndrome	7.07e-05	0.000246	CcSEcCtD
Guanabenz—Fatigue—Valproic Acid—epilepsy syndrome	7.07e-05	0.000246	CcSEcCtD
Guanabenz—Anxiety—Gabapentin—epilepsy syndrome	7.06e-05	0.000246	CcSEcCtD
Guanabenz—Anorexia—Pregabalin—epilepsy syndrome	7.06e-05	0.000246	CcSEcCtD
Guanabenz—Dizziness—Carbamazepine—epilepsy syndrome	7.06e-05	0.000246	CcSEcCtD
Guanabenz—Diarrhoea—Lamotrigine—epilepsy syndrome	7.06e-05	0.000246	CcSEcCtD
Guanabenz—Headache—Clonazepam—epilepsy syndrome	7.05e-05	0.000246	CcSEcCtD
Guanabenz—Rash—Phenytoin—epilepsy syndrome	7.05e-05	0.000246	CcSEcCtD
Guanabenz—Dermatitis—Phenytoin—epilepsy syndrome	7.04e-05	0.000245	CcSEcCtD
Guanabenz—Rash—Oxcarbazepine—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Constipation—Valproic Acid—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Pain—Valproic Acid—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Dermatitis—Oxcarbazepine—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Headache—Phenytoin—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Erythema—Topiramate—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Malnutrition—Topiramate—epilepsy syndrome	7.01e-05	0.000244	CcSEcCtD
Guanabenz—Discomfort—Gabapentin—epilepsy syndrome	7e-05	0.000244	CcSEcCtD
Guanabenz—Headache—Oxcarbazepine—epilepsy syndrome	6.97e-05	0.000243	CcSEcCtD
Guanabenz—Nausea—Zonisamide—epilepsy syndrome	6.94e-05	0.000242	CcSEcCtD
Guanabenz—Dry mouth—Gabapentin—epilepsy syndrome	6.93e-05	0.000242	CcSEcCtD
Guanabenz—Hypotension—Pregabalin—epilepsy syndrome	6.93e-05	0.000241	CcSEcCtD
Guanabenz—Flatulence—Topiramate—epilepsy syndrome	6.9e-05	0.00024	CcSEcCtD
Guanabenz—Tension—Topiramate—epilepsy syndrome	6.87e-05	0.000239	CcSEcCtD
Guanabenz—Confusional state—Gabapentin—epilepsy syndrome	6.85e-05	0.000239	CcSEcCtD
Guanabenz—Dizziness—Lamotrigine—epilepsy syndrome	6.82e-05	0.000238	CcSEcCtD
Guanabenz—Nervousness—Topiramate—epilepsy syndrome	6.8e-05	0.000237	CcSEcCtD
Guanabenz—Oedema—Gabapentin—epilepsy syndrome	6.8e-05	0.000237	CcSEcCtD
Guanabenz—Vomiting—Carbamazepine—epilepsy syndrome	6.79e-05	0.000236	CcSEcCtD
Guanabenz—Back pain—Topiramate—epilepsy syndrome	6.78e-05	0.000236	CcSEcCtD
Guanabenz—Feeling abnormal—Valproic Acid—epilepsy syndrome	6.76e-05	0.000235	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	6.75e-05	0.000235	CcSEcCtD
Guanabenz—Infection—Gabapentin—epilepsy syndrome	6.75e-05	0.000235	CcSEcCtD
Guanabenz—Muscle spasms—Topiramate—epilepsy syndrome	6.74e-05	0.000235	CcSEcCtD
Guanabenz—Rash—Carbamazepine—epilepsy syndrome	6.73e-05	0.000234	CcSEcCtD
Guanabenz—Dermatitis—Carbamazepine—epilepsy syndrome	6.72e-05	0.000234	CcSEcCtD
Guanabenz—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	6.7e-05	0.000234	CcSEcCtD
Guanabenz—Nausea—Clonazepam—epilepsy syndrome	6.69e-05	0.000233	CcSEcCtD
Guanabenz—Headache—Carbamazepine—epilepsy syndrome	6.69e-05	0.000233	CcSEcCtD
Guanabenz—Shock—Gabapentin—epilepsy syndrome	6.69e-05	0.000233	CcSEcCtD
Guanabenz—Nervous system disorder—Gabapentin—epilepsy syndrome	6.66e-05	0.000232	CcSEcCtD
Guanabenz—Paraesthesia—Pregabalin—epilepsy syndrome	6.65e-05	0.000232	CcSEcCtD
Guanabenz—Thrombocytopenia—Gabapentin—epilepsy syndrome	6.65e-05	0.000232	CcSEcCtD
Guanabenz—Nausea—Phenytoin—epilepsy syndrome	6.64e-05	0.000231	CcSEcCtD
Guanabenz—Tachycardia—Gabapentin—epilepsy syndrome	6.63e-05	0.000231	CcSEcCtD
Guanabenz—Dyspnoea—Pregabalin—epilepsy syndrome	6.61e-05	0.00023	CcSEcCtD
Guanabenz—Nausea—Oxcarbazepine—epilepsy syndrome	6.61e-05	0.00023	CcSEcCtD
Guanabenz—Vision blurred—Topiramate—epilepsy syndrome	6.6e-05	0.00023	CcSEcCtD
Guanabenz—Skin disorder—Gabapentin—epilepsy syndrome	6.6e-05	0.00023	CcSEcCtD
Guanabenz—Vomiting—Lamotrigine—epilepsy syndrome	6.56e-05	0.000228	CcSEcCtD
Guanabenz—Urticaria—Valproic Acid—epilepsy syndrome	6.51e-05	0.000227	CcSEcCtD
Guanabenz—Rash—Lamotrigine—epilepsy syndrome	6.5e-05	0.000227	CcSEcCtD
Guanabenz—Ill-defined disorder—Topiramate—epilepsy syndrome	6.5e-05	0.000226	CcSEcCtD
Guanabenz—Dermatitis—Lamotrigine—epilepsy syndrome	6.5e-05	0.000226	CcSEcCtD
Guanabenz—Abdominal pain—Valproic Acid—epilepsy syndrome	6.48e-05	0.000226	CcSEcCtD
Guanabenz—Body temperature increased—Valproic Acid—epilepsy syndrome	6.48e-05	0.000226	CcSEcCtD
Guanabenz—Anorexia—Gabapentin—epilepsy syndrome	6.48e-05	0.000226	CcSEcCtD
Guanabenz—Anaemia—Topiramate—epilepsy syndrome	6.48e-05	0.000226	CcSEcCtD
Guanabenz—Headache—Lamotrigine—epilepsy syndrome	6.46e-05	0.000225	CcSEcCtD
Guanabenz—Decreased appetite—Pregabalin—epilepsy syndrome	6.44e-05	0.000224	CcSEcCtD
Guanabenz—Agitation—Topiramate—epilepsy syndrome	6.44e-05	0.000224	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	6.4e-05	0.000223	CcSEcCtD
Guanabenz—Fatigue—Pregabalin—epilepsy syndrome	6.39e-05	0.000223	CcSEcCtD
Guanabenz—Hypotension—Gabapentin—epilepsy syndrome	6.35e-05	0.000221	CcSEcCtD
Guanabenz—Nausea—Carbamazepine—epilepsy syndrome	6.34e-05	0.000221	CcSEcCtD
Guanabenz—Pain—Pregabalin—epilepsy syndrome	6.34e-05	0.000221	CcSEcCtD
Guanabenz—Constipation—Pregabalin—epilepsy syndrome	6.34e-05	0.000221	CcSEcCtD
Guanabenz—Malaise—Topiramate—epilepsy syndrome	6.32e-05	0.00022	CcSEcCtD
Guanabenz—Syncope—Topiramate—epilepsy syndrome	6.28e-05	0.000219	CcSEcCtD
Guanabenz—Leukopenia—Topiramate—epilepsy syndrome	6.27e-05	0.000218	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	6.19e-05	0.000216	CcSEcCtD
Guanabenz—Loss of consciousness—Topiramate—epilepsy syndrome	6.16e-05	0.000214	CcSEcCtD
Guanabenz—Nausea—Lamotrigine—epilepsy syndrome	6.13e-05	0.000213	CcSEcCtD
Guanabenz—Cough—Topiramate—epilepsy syndrome	6.11e-05	0.000213	CcSEcCtD
Guanabenz—Feeling abnormal—Pregabalin—epilepsy syndrome	6.11e-05	0.000213	CcSEcCtD
Guanabenz—Paraesthesia—Gabapentin—epilepsy syndrome	6.1e-05	0.000213	CcSEcCtD
Guanabenz—Gastrointestinal pain—Pregabalin—epilepsy syndrome	6.06e-05	0.000211	CcSEcCtD
Guanabenz—Dyspnoea—Gabapentin—epilepsy syndrome	6.06e-05	0.000211	CcSEcCtD
Guanabenz—Hypertension—Topiramate—epilepsy syndrome	6.05e-05	0.000211	CcSEcCtD
Guanabenz—Hypersensitivity—Valproic Acid—epilepsy syndrome	6.04e-05	0.00021	CcSEcCtD
Guanabenz—Dyspepsia—Gabapentin—epilepsy syndrome	5.98e-05	0.000208	CcSEcCtD
Guanabenz—Myalgia—Topiramate—epilepsy syndrome	5.96e-05	0.000208	CcSEcCtD
Guanabenz—Arthralgia—Topiramate—epilepsy syndrome	5.96e-05	0.000208	CcSEcCtD
Guanabenz—Chest pain—Topiramate—epilepsy syndrome	5.96e-05	0.000208	CcSEcCtD
Guanabenz—Anxiety—Topiramate—epilepsy syndrome	5.94e-05	0.000207	CcSEcCtD
Guanabenz—Decreased appetite—Gabapentin—epilepsy syndrome	5.91e-05	0.000206	CcSEcCtD
Guanabenz—Discomfort—Topiramate—epilepsy syndrome	5.89e-05	0.000205	CcSEcCtD
Guanabenz—Urticaria—Pregabalin—epilepsy syndrome	5.89e-05	0.000205	CcSEcCtD
Guanabenz—Asthenia—Valproic Acid—epilepsy syndrome	5.88e-05	0.000205	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	5.87e-05	0.000204	CcSEcCtD
Guanabenz—Fatigue—Gabapentin—epilepsy syndrome	5.86e-05	0.000204	CcSEcCtD
Guanabenz—Body temperature increased—Pregabalin—epilepsy syndrome	5.86e-05	0.000204	CcSEcCtD
Guanabenz—Abdominal pain—Pregabalin—epilepsy syndrome	5.86e-05	0.000204	CcSEcCtD
Guanabenz—Dry mouth—Topiramate—epilepsy syndrome	5.83e-05	0.000203	CcSEcCtD
Guanabenz—Pain—Gabapentin—epilepsy syndrome	5.81e-05	0.000202	CcSEcCtD
Guanabenz—Constipation—Gabapentin—epilepsy syndrome	5.81e-05	0.000202	CcSEcCtD
Guanabenz—Pruritus—Valproic Acid—epilepsy syndrome	5.8e-05	0.000202	CcSEcCtD
Guanabenz—Confusional state—Topiramate—epilepsy syndrome	5.77e-05	0.000201	CcSEcCtD
Guanabenz—Oedema—Topiramate—epilepsy syndrome	5.72e-05	0.000199	CcSEcCtD
Guanabenz—Infection—Topiramate—epilepsy syndrome	5.68e-05	0.000198	CcSEcCtD
Guanabenz—Shock—Topiramate—epilepsy syndrome	5.63e-05	0.000196	CcSEcCtD
Guanabenz—Diarrhoea—Valproic Acid—epilepsy syndrome	5.61e-05	0.000195	CcSEcCtD
Guanabenz—Nervous system disorder—Topiramate—epilepsy syndrome	5.61e-05	0.000195	CcSEcCtD
Guanabenz—Feeling abnormal—Gabapentin—epilepsy syndrome	5.6e-05	0.000195	CcSEcCtD
Guanabenz—Thrombocytopenia—Topiramate—epilepsy syndrome	5.6e-05	0.000195	CcSEcCtD
Guanabenz—Tachycardia—Topiramate—epilepsy syndrome	5.58e-05	0.000194	CcSEcCtD
Guanabenz—Gastrointestinal pain—Gabapentin—epilepsy syndrome	5.56e-05	0.000194	CcSEcCtD
Guanabenz—Skin disorder—Topiramate—epilepsy syndrome	5.55e-05	0.000193	CcSEcCtD
Guanabenz—Hypersensitivity—Pregabalin—epilepsy syndrome	5.46e-05	0.00019	CcSEcCtD
Guanabenz—Anorexia—Topiramate—epilepsy syndrome	5.45e-05	0.00019	CcSEcCtD
Guanabenz—Dizziness—Valproic Acid—epilepsy syndrome	5.42e-05	0.000189	CcSEcCtD
Guanabenz—Urticaria—Gabapentin—epilepsy syndrome	5.4e-05	0.000188	CcSEcCtD
Guanabenz—Abdominal pain—Gabapentin—epilepsy syndrome	5.37e-05	0.000187	CcSEcCtD
Guanabenz—Body temperature increased—Gabapentin—epilepsy syndrome	5.37e-05	0.000187	CcSEcCtD
Guanabenz—Hypotension—Topiramate—epilepsy syndrome	5.34e-05	0.000186	CcSEcCtD
Guanabenz—Asthenia—Pregabalin—epilepsy syndrome	5.32e-05	0.000185	CcSEcCtD
Guanabenz—Pruritus—Pregabalin—epilepsy syndrome	5.24e-05	0.000183	CcSEcCtD
Guanabenz—Vomiting—Valproic Acid—epilepsy syndrome	5.21e-05	0.000182	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	5.21e-05	0.000181	CcSEcCtD
Guanabenz—Rash—Valproic Acid—epilepsy syndrome	5.17e-05	0.00018	CcSEcCtD
Guanabenz—Dermatitis—Valproic Acid—epilepsy syndrome	5.16e-05	0.00018	CcSEcCtD
Guanabenz—Headache—Valproic Acid—epilepsy syndrome	5.14e-05	0.000179	CcSEcCtD
Guanabenz—Paraesthesia—Topiramate—epilepsy syndrome	5.13e-05	0.000179	CcSEcCtD
Guanabenz—Dyspnoea—Topiramate—epilepsy syndrome	5.1e-05	0.000178	CcSEcCtD
Guanabenz—Diarrhoea—Pregabalin—epilepsy syndrome	5.07e-05	0.000177	CcSEcCtD
Guanabenz—Dyspepsia—Topiramate—epilepsy syndrome	5.03e-05	0.000175	CcSEcCtD
Guanabenz—Hypersensitivity—Gabapentin—epilepsy syndrome	5.01e-05	0.000174	CcSEcCtD
Guanabenz—Decreased appetite—Topiramate—epilepsy syndrome	4.97e-05	0.000173	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Topiramate—epilepsy syndrome	4.94e-05	0.000172	CcSEcCtD
Guanabenz—Fatigue—Topiramate—epilepsy syndrome	4.93e-05	0.000172	CcSEcCtD
Guanabenz—Dizziness—Pregabalin—epilepsy syndrome	4.9e-05	0.000171	CcSEcCtD
Guanabenz—Constipation—Topiramate—epilepsy syndrome	4.89e-05	0.00017	CcSEcCtD
Guanabenz—Pain—Topiramate—epilepsy syndrome	4.89e-05	0.00017	CcSEcCtD
Guanabenz—Asthenia—Gabapentin—epilepsy syndrome	4.88e-05	0.00017	CcSEcCtD
Guanabenz—Nausea—Valproic Acid—epilepsy syndrome	4.87e-05	0.00017	CcSEcCtD
Guanabenz—Pruritus—Gabapentin—epilepsy syndrome	4.81e-05	0.000167	CcSEcCtD
Guanabenz—Vomiting—Pregabalin—epilepsy syndrome	4.71e-05	0.000164	CcSEcCtD
Guanabenz—Feeling abnormal—Topiramate—epilepsy syndrome	4.71e-05	0.000164	CcSEcCtD
Guanabenz—Gastrointestinal pain—Topiramate—epilepsy syndrome	4.68e-05	0.000163	CcSEcCtD
Guanabenz—Rash—Pregabalin—epilepsy syndrome	4.67e-05	0.000163	CcSEcCtD
Guanabenz—Dermatitis—Pregabalin—epilepsy syndrome	4.67e-05	0.000163	CcSEcCtD
Guanabenz—Diarrhoea—Gabapentin—epilepsy syndrome	4.65e-05	0.000162	CcSEcCtD
Guanabenz—Headache—Pregabalin—epilepsy syndrome	4.64e-05	0.000162	CcSEcCtD
Guanabenz—Urticaria—Topiramate—epilepsy syndrome	4.54e-05	0.000158	CcSEcCtD
Guanabenz—Abdominal pain—Topiramate—epilepsy syndrome	4.52e-05	0.000157	CcSEcCtD
Guanabenz—Body temperature increased—Topiramate—epilepsy syndrome	4.52e-05	0.000157	CcSEcCtD
Guanabenz—Dizziness—Gabapentin—epilepsy syndrome	4.49e-05	0.000157	CcSEcCtD
Guanabenz—Nausea—Pregabalin—epilepsy syndrome	4.4e-05	0.000153	CcSEcCtD
Guanabenz—Vomiting—Gabapentin—epilepsy syndrome	4.32e-05	0.000151	CcSEcCtD
Guanabenz—Rash—Gabapentin—epilepsy syndrome	4.28e-05	0.000149	CcSEcCtD
Guanabenz—Dermatitis—Gabapentin—epilepsy syndrome	4.28e-05	0.000149	CcSEcCtD
Guanabenz—Headache—Gabapentin—epilepsy syndrome	4.26e-05	0.000148	CcSEcCtD
Guanabenz—Hypersensitivity—Topiramate—epilepsy syndrome	4.21e-05	0.000147	CcSEcCtD
Guanabenz—Asthenia—Topiramate—epilepsy syndrome	4.1e-05	0.000143	CcSEcCtD
Guanabenz—Pruritus—Topiramate—epilepsy syndrome	4.05e-05	0.000141	CcSEcCtD
Guanabenz—Nausea—Gabapentin—epilepsy syndrome	4.04e-05	0.000141	CcSEcCtD
Guanabenz—Diarrhoea—Topiramate—epilepsy syndrome	3.91e-05	0.000136	CcSEcCtD
Guanabenz—Dizziness—Topiramate—epilepsy syndrome	3.78e-05	0.000132	CcSEcCtD
Guanabenz—Vomiting—Topiramate—epilepsy syndrome	3.64e-05	0.000127	CcSEcCtD
Guanabenz—Rash—Topiramate—epilepsy syndrome	3.6e-05	0.000126	CcSEcCtD
Guanabenz—Dermatitis—Topiramate—epilepsy syndrome	3.6e-05	0.000125	CcSEcCtD
Guanabenz—Headache—Topiramate—epilepsy syndrome	3.58e-05	0.000125	CcSEcCtD
Guanabenz—Nausea—Topiramate—epilepsy syndrome	3.4e-05	0.000118	CcSEcCtD
Guanabenz—ADRA2A—Signaling Pathways—GABBR1—epilepsy syndrome	1.31e-05	0.000113	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCR2—epilepsy syndrome	1.31e-05	0.000112	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NTRK2—epilepsy syndrome	1.31e-05	0.000112	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SST—epilepsy syndrome	1.31e-05	0.000112	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NT5E—epilepsy syndrome	1.31e-05	0.000112	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALAD—epilepsy syndrome	1.31e-05	0.000112	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—HTR2A—epilepsy syndrome	1.3e-05	0.000112	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—DUSP6—epilepsy syndrome	1.3e-05	0.000112	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ADRA2A—epilepsy syndrome	1.28e-05	0.00011	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PLAT—epilepsy syndrome	1.28e-05	0.00011	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—AVP—epilepsy syndrome	1.27e-05	0.00011	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.26e-05	0.000108	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PTK2B—epilepsy syndrome	1.26e-05	0.000108	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TSC1—epilepsy syndrome	1.26e-05	0.000108	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HRH3—epilepsy syndrome	1.26e-05	0.000108	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—SRC—epilepsy syndrome	1.25e-05	0.000108	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CACNA1A—epilepsy syndrome	1.25e-05	0.000107	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALDH7A1—epilepsy syndrome	1.25e-05	0.000107	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—AGT—epilepsy syndrome	1.24e-05	0.000106	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—OPRM1—epilepsy syndrome	1.24e-05	0.000106	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CXCL12—epilepsy syndrome	1.23e-05	0.000106	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—BDKRB2—epilepsy syndrome	1.23e-05	0.000106	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—POMC—epilepsy syndrome	1.23e-05	0.000106	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PRKCB—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCR2—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NTRK2—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SST—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—VEGFA—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ST3GAL3—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP2D6—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL6ST—epilepsy syndrome	1.22e-05	0.000105	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—DUSP6—epilepsy syndrome	1.21e-05	0.000104	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CNR1—epilepsy syndrome	1.21e-05	0.000104	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JUNB—epilepsy syndrome	1.21e-05	0.000104	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PLCB1—epilepsy syndrome	1.2e-05	0.000103	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ADSL—epilepsy syndrome	1.2e-05	0.000103	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ADRA2A—epilepsy syndrome	1.2e-05	0.000103	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—CCR5—epilepsy syndrome	1.19e-05	0.000103	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PLAT—epilepsy syndrome	1.19e-05	0.000102	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HTR7—epilepsy syndrome	1.18e-05	0.000101	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GLUL—epilepsy syndrome	1.17e-05	0.000101	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—SRC—epilepsy syndrome	1.17e-05	0.000101	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCR3—epilepsy syndrome	1.17e-05	0.0001	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—HTR2A—epilepsy syndrome	1.17e-05	0.0001	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—BCHE—epilepsy syndrome	1.16e-05	9.95e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CACNA1D—epilepsy syndrome	1.15e-05	9.9e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CXCL12—epilepsy syndrome	1.15e-05	9.88e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—BDKRB2—epilepsy syndrome	1.15e-05	9.88e-05	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—POMC—epilepsy syndrome	1.15e-05	9.87e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—AKT1—epilepsy syndrome	1.15e-05	9.86e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PRKCB—epilepsy syndrome	1.14e-05	9.83e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HBEGF—epilepsy syndrome	1.14e-05	9.83e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—VEGFA—epilepsy syndrome	1.14e-05	9.81e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL6ST—epilepsy syndrome	1.14e-05	9.8e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NPY—epilepsy syndrome	1.14e-05	9.78e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ATP2A2—epilepsy syndrome	1.14e-05	9.78e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JUNB—epilepsy syndrome	1.13e-05	9.7e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CNR1—epilepsy syndrome	1.13e-05	9.7e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PLCB1—epilepsy syndrome	1.12e-05	9.66e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AKT3—epilepsy syndrome	1.12e-05	9.65e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—HMOX1—epilepsy syndrome	1.12e-05	9.61e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—POMC—epilepsy syndrome	1.12e-05	9.59e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—AGT—epilepsy syndrome	1.11e-05	9.52e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—SLC2A1—epilepsy syndrome	1.1e-05	9.49e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CAT—epilepsy syndrome	1.1e-05	9.48e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HTR7—epilepsy syndrome	1.1e-05	9.46e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HSPB1—epilepsy syndrome	1.1e-05	9.44e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CXCL2—epilepsy syndrome	1.1e-05	9.44e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—OXT—epilepsy syndrome	1.1e-05	9.44e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CRH—epilepsy syndrome	1.1e-05	9.44e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCL3—epilepsy syndrome	1.1e-05	9.44e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ADAM10—epilepsy syndrome	1.1e-05	9.43e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PLCB1—epilepsy syndrome	1.09e-05	9.39e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—CCL2—epilepsy syndrome	1.09e-05	9.38e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—TH—epilepsy syndrome	1.09e-05	9.35e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—CCR5—epilepsy syndrome	1.08e-05	9.31e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—TXNRD1—epilepsy syndrome	1.08e-05	9.26e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ABCB1—epilepsy syndrome	1.07e-05	9.22e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HBEGF—epilepsy syndrome	1.07e-05	9.19e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—HTR2A—epilepsy syndrome	1.06e-05	9.11e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AKT3—epilepsy syndrome	1.05e-05	9.02e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AQP1—epilepsy syndrome	1.05e-05	8.99e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—POMC—epilepsy syndrome	1.04e-05	8.96e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—S100B—epilepsy syndrome	1.04e-05	8.91e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SOCS3—epilepsy syndrome	1.03e-05	8.83e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CDC42—epilepsy syndrome	1.02e-05	8.81e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ADAM10—epilepsy syndrome	1.02e-05	8.81e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	1.02e-05	8.8e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TSC1—epilepsy syndrome	1.02e-05	8.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PTK2B—epilepsy syndrome	1.02e-05	8.77e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—CCL2—epilepsy syndrome	1.02e-05	8.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—AGT—epilepsy syndrome	1.01e-05	8.65e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—epilepsy syndrome	1e-05	8.63e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GPX1—epilepsy syndrome	9.98e-06	8.58e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCR2—epilepsy syndrome	9.93e-06	8.54e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SST—epilepsy syndrome	9.93e-06	8.54e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NTRK2—epilepsy syndrome	9.93e-06	8.54e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AVP—epilepsy syndrome	9.92e-06	8.53e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—DUSP6—epilepsy syndrome	9.84e-06	8.46e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—S100B—epilepsy syndrome	9.69e-06	8.33e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PLAT—epilepsy syndrome	9.68e-06	8.32e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SOCS3—epilepsy syndrome	9.59e-06	8.25e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CDC42—epilepsy syndrome	9.57e-06	8.23e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—SRC—epilepsy syndrome	9.51e-06	8.18e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CHRM3—epilepsy syndrome	9.46e-06	8.13e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—KCNJ11—epilepsy syndrome	9.46e-06	8.13e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HES1—epilepsy syndrome	9.38e-06	8.06e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	9.34e-06	8.02e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CXCL12—epilepsy syndrome	9.34e-06	8.02e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—POMC—epilepsy syndrome	9.32e-06	8.01e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	9.29e-06	7.99e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—VEGFA—epilepsy syndrome	9.27e-06	7.97e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AVP—epilepsy syndrome	9.26e-06	7.96e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	9.26e-06	7.96e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JUNB—epilepsy syndrome	9.16e-06	7.88e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CNR1—epilepsy syndrome	9.16e-06	7.88e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PLCB1—epilepsy syndrome	9.13e-06	7.85e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FYN—epilepsy syndrome	9.12e-06	7.84e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—H2AFX—epilepsy syndrome	9.09e-06	7.81e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—HMOX1—epilepsy syndrome	9.08e-06	7.81e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MEF2C—epilepsy syndrome	9.07e-06	7.8e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CAT—epilepsy syndrome	8.96e-06	7.7e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HTR7—epilepsy syndrome	8.94e-06	7.68e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—AGT—epilepsy syndrome	8.81e-06	7.57e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—YWHAZ—epilepsy syndrome	8.77e-06	7.54e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HES1—epilepsy syndrome	8.76e-06	7.53e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—AGT—epilepsy syndrome	8.75e-06	7.52e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ABCB1—epilepsy syndrome	8.72e-06	7.49e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HBEGF—epilepsy syndrome	8.68e-06	7.46e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NGF—epilepsy syndrome	8.67e-06	7.45e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—APOE—epilepsy syndrome	8.63e-06	7.42e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—APOE—epilepsy syndrome	8.57e-06	7.37e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FYN—epilepsy syndrome	8.52e-06	7.32e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AKT3—epilepsy syndrome	8.52e-06	7.32e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—H2AFX—epilepsy syndrome	8.49e-06	7.3e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MEF2C—epilepsy syndrome	8.47e-06	7.28e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—POMC—epilepsy syndrome	8.46e-06	7.28e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCR5—epilepsy syndrome	8.43e-06	7.25e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ADAM10—epilepsy syndrome	8.32e-06	7.15e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—CCL2—epilepsy syndrome	8.28e-06	7.12e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HTR2A—epilepsy syndrome	8.25e-06	7.09e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—YWHAZ—epilepsy syndrome	8.19e-06	7.04e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GPX1—epilepsy syndrome	8.1e-06	6.97e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NGF—epilepsy syndrome	8.1e-06	6.96e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCR5—epilepsy syndrome	7.88e-06	6.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—S100B—epilepsy syndrome	7.87e-06	6.76e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TSC2—epilepsy syndrome	7.84e-06	6.74e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AGT—epilepsy syndrome	7.83e-06	6.73e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—AKT1—epilepsy syndrome	7.79e-06	6.7e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SOCS3—epilepsy syndrome	7.79e-06	6.7e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CDC42—epilepsy syndrome	7.77e-06	6.68e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ABCG2—epilepsy syndrome	7.71e-06	6.63e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HTR2A—epilepsy syndrome	7.71e-06	6.63e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—APOE—epilepsy syndrome	7.67e-06	6.6e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AVP—epilepsy syndrome	7.52e-06	6.47e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KDR—epilepsy syndrome	7.52e-06	6.46e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2C19—epilepsy syndrome	7.51e-06	6.46e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP11A1—epilepsy syndrome	7.47e-06	6.42e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	7.41e-06	6.37e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—POMC—epilepsy syndrome	7.36e-06	6.33e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TSC2—epilepsy syndrome	7.32e-06	6.3e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AGT—epilepsy syndrome	7.31e-06	6.29e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—AKT1—epilepsy syndrome	7.28e-06	6.26e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PRKCB—epilepsy syndrome	7.23e-06	6.22e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL6ST—epilepsy syndrome	7.21e-06	6.19e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—APOE—epilepsy syndrome	7.17e-06	6.16e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HES1—epilepsy syndrome	7.12e-06	6.12e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—AGT—epilepsy syndrome	7.1e-06	6.11e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KDR—epilepsy syndrome	7.02e-06	6.04e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—APOE—epilepsy syndrome	6.96e-06	5.98e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FYN—epilepsy syndrome	6.92e-06	5.95e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—H2AFX—epilepsy syndrome	6.89e-06	5.93e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MEF2C—epilepsy syndrome	6.88e-06	5.92e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PRKCB—epilepsy syndrome	6.76e-06	5.81e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	6.76e-06	5.81e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP2D6—epilepsy syndrome	6.74e-06	5.79e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL6ST—epilepsy syndrome	6.73e-06	5.79e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALB—epilepsy syndrome	6.71e-06	5.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	6.65e-06	5.72e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—POMC—epilepsy syndrome	6.59e-06	5.67e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NGF—epilepsy syndrome	6.58e-06	5.65e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CCL2—epilepsy syndrome	6.45e-06	5.54e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ADRA2A—epilepsy syndrome	6.41e-06	5.51e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCR5—epilepsy syndrome	6.4e-06	5.5e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—BCHE—epilepsy syndrome	6.39e-06	5.49e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HTR2A—epilepsy syndrome	6.26e-06	5.38e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—POMC—epilepsy syndrome	6.16e-06	5.29e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—SLC2A1—epilepsy syndrome	6.09e-06	5.24e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PLCB1—epilepsy syndrome	6.03e-06	5.18e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CCL2—epilepsy syndrome	6.02e-06	5.18e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—TH—epilepsy syndrome	6.01e-06	5.16e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—POMC—epilepsy syndrome	5.98e-06	5.14e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TSC2—epilepsy syndrome	5.95e-06	5.11e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AGT—epilepsy syndrome	5.94e-06	5.11e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—AKT1—epilepsy syndrome	5.91e-06	5.08e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	5.91e-06	5.08e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTGS2—epilepsy syndrome	5.87e-06	5.05e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FGF2—epilepsy syndrome	5.83e-06	5.01e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—APOE—epilepsy syndrome	5.82e-06	5e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KDR—epilepsy syndrome	5.7e-06	4.9e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PRKCB—epilepsy syndrome	5.49e-06	4.72e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL6ST—epilepsy syndrome	5.47e-06	4.7e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALB—epilepsy syndrome	5.45e-06	4.69e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FGF2—epilepsy syndrome	5.44e-06	4.68e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—RELA—epilepsy syndrome	5.41e-06	4.65e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MTOR—epilepsy syndrome	5.31e-06	4.56e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—RELA—epilepsy syndrome	5.05e-06	4.34e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HMOX1—epilepsy syndrome	5.01e-06	4.31e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—POMC—epilepsy syndrome	5e-06	4.3e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MTOR—epilepsy syndrome	4.96e-06	4.26e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CAT—epilepsy syndrome	4.95e-06	4.25e-05	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—AKT1—epilepsy syndrome	4.93e-06	4.23e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CCL2—epilepsy syndrome	4.89e-06	4.21e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CASP3—epilepsy syndrome	4.88e-06	4.19e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ABCB1—epilepsy syndrome	4.81e-06	4.14e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTGS2—epilepsy syndrome	4.77e-06	4.1e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JUN—epilepsy syndrome	4.74e-06	4.07e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MMP9—epilepsy syndrome	4.61e-06	3.96e-05	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—AKT1—epilepsy syndrome	4.6e-06	3.95e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CASP3—epilepsy syndrome	4.56e-06	3.92e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GPX1—epilepsy syndrome	4.47e-06	3.84e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—AKT1—epilepsy syndrome	4.47e-06	3.84e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JUN—epilepsy syndrome	4.43e-06	3.81e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FGF2—epilepsy syndrome	4.42e-06	3.8e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MMP9—epilepsy syndrome	4.31e-06	3.7e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SRC—epilepsy syndrome	4.25e-06	3.65e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—AKT1—epilepsy syndrome	4.18e-06	3.59e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—VEGFA—epilepsy syndrome	4.14e-06	3.56e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—RELA—epilepsy syndrome	4.1e-06	3.53e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MTOR—epilepsy syndrome	4.03e-06	3.46e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SRC—epilepsy syndrome	3.97e-06	3.41e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AGT—epilepsy syndrome	3.92e-06	3.37e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—VEGFA—epilepsy syndrome	3.87e-06	3.33e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—APOE—epilepsy syndrome	3.84e-06	3.3e-05	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	3.74e-06	3.21e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CASP3—epilepsy syndrome	3.7e-06	3.18e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JUN—epilepsy syndrome	3.6e-06	3.09e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MMP9—epilepsy syndrome	3.5e-06	3.01e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—AKT1—epilepsy syndrome	3.39e-06	2.92e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—POMC—epilepsy syndrome	3.3e-06	2.84e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SRC—epilepsy syndrome	3.23e-06	2.77e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—VEGFA—epilepsy syndrome	3.14e-06	2.7e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALB—epilepsy syndrome	3.01e-06	2.59e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—AKT1—epilepsy syndrome	2.95e-06	2.54e-05	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—AKT1—epilepsy syndrome	2.64e-06	2.27e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTGS2—epilepsy syndrome	2.63e-06	2.26e-05	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—AKT1—epilepsy syndrome	2.47e-06	2.12e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—AKT1—epilepsy syndrome	2.4e-06	2.06e-05	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—AKT1—epilepsy syndrome	2e-06	1.72e-05	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—AKT1—epilepsy syndrome	1.32e-06	1.14e-05	CbGpPWpGaD
